Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia

The molecular biological role of the sigma-1 receptor (Sig-1R) has attracted much attention. Evidence suggests that the Sig-1R engaged in modulating NMDA and dopamine receptors is involved in the pathophysiology of schizophrenia and the mechanism of psychotropic drug efficacy. However, whether the Sig-1R genotype affects brain function in schizophrenia in vivo remains unknown. We investigated the association between Sig-1R functional polymorphism (Gln2Pro) and brain function in schizophrenia. The subjects were 40 patients with schizophrenia and 60 healthy controls, all right-handed, who gave written informed consent to participate. Signals, detected from prefrontal regions by 52-channel near-infrared spectroscopy (NIRS) during cognitive activation, were compared between two Sig1-R genotype subgroups (Gln/Gln individuals and Pro carriers) matched for age, gender, premorbid IQ and task performance. The prefrontal hemodynamic response of healthy controls during the verbal fluency task was higher than that of patients with schizophrenia. For the patients with schizophrenia, even after controlling the effect of medication, the [oxy-Hb] increase in the prefrontal cortex of the Gln/Gln genotype group was significantly greater than that of the Pro carriers (false discovery rate corrected p<0.05). Clinical symptoms were not significantly different between the two Sig-1R genotype subgroups. These differences were not significant in the healthy controls. This is the first functional imaging genetics study that implicated the association between Sig-1R genotype and prefrontal cortical function in schizophrenia in vivo. Our findings also suggest that the prefrontal hemodynamic response assessed by noninvasive and less demanding NIRS is a useful intermediate phenotype for translational research in schizophrenia.

[1]  Z. Vogel,et al.  Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. , 1994, The Journal of pharmacology and experimental therapeutics.

[2]  Makoto Ito,et al.  Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive brain activation study , 2004, Biological Psychiatry.

[3]  Archana K. Singh,et al.  Exploring the false discovery rate in multichannel NIRS , 2006, NeuroImage.

[4]  M. Tamura,et al.  Interpretation of near-infrared spectroscopy signals: a study with a newly developed perfused rat brain model. , 2001, Journal of applied physiology.

[5]  Andreas Meyer-Lindenberg,et al.  False positives in imaging genetics , 2008, NeuroImage.

[6]  R. C. Oldfield The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[7]  Teruo Hayashi,et al.  Regulating ankyrin dynamics: Roles of sigma-1 receptors. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Cabeza,et al.  Imaging Cognition II: An Empirical Review of 275 PET and fMRI Studies , 2000, Journal of Cognitive Neuroscience.

[9]  S. Higuchi,et al.  Functional polymorphisms in the sigma1 receptor gene associated with alcoholism , 2003, Biological Psychiatry.

[10]  M. Itokawa,et al.  Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia , 1998, Neuroscience Letters.

[11]  D. Boas,et al.  Non-invasive neuroimaging using near-infrared light , 2002, Biological Psychiatry.

[12]  Masato Fukuda,et al.  Reduced frontopolar activation during verbal fluency task in schizophrenia: A multi-channel near-infrared spectroscopy study , 2008, Schizophrenia Research.

[13]  L. Clare,et al.  A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia , 2005, Neuropsychology Review.

[14]  C. Montigny,et al.  N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors , 1990 .

[15]  A. Privat,et al.  The anti-amnesic effects of sigma1 (σ 1) receptor agonists confirmed by in vivo antisense strategy in the mouse , 2001, Brain Research.

[16]  Y. Hoshi Functional near-infrared optical imaging: utility and limitations in human brain mapping. , 2003, Psychophysiology.

[17]  A. Fallgatter,et al.  Reduced frontal functional asymmetry in schizophrenia during a cued continuous performance test assessed with near-infrared spectroscopy. , 2000, Schizophrenia bulletin.

[18]  Mitsutoshi Yamamoto,et al.  A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  H. Silver Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia , 2004, Expert opinion on pharmacotherapy.

[20]  J. Hedreen,et al.  Sigma receptors in post-mortem human brains. , 1988, The Journal of pharmacology and experimental therapeutics.

[21]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[22]  Teruo Hayashi,et al.  Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. , 2003, Current medicinal chemistry.

[23]  A. Prescott,et al.  Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo , 2004, Cancer Research.

[24]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Várnai,et al.  Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels , 2006, The Journal of cell biology.

[26]  P. Goldman-Rakic,et al.  D1 receptors in prefrontal cells and circuits , 2000, Brain Research Reviews.

[27]  A. Zhang,et al.  Sigma and PCP receptors in human frontal cortex membranes. , 1988, European journal of pharmacology.

[28]  K. Kasai,et al.  Estimation of premorbid IQ in individuals with Alzheimer’s disease using Japanese ideographic script (Kanji) compound words: Japanese version of National Adult Reading Test , 2006, Psychiatry and clinical neurosciences.

[29]  U. Spampinato,et al.  Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo , 2003, Neuropharmacology.

[30]  John G. Csernansky,et al.  Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings , 2006, Schizophrenia Research.

[31]  Teruo Hayashi,et al.  σ-1 Receptor Ligands , 2004 .

[32]  Masako Okamoto,et al.  Three-dimensional probabilistic anatomical cranio-cerebral correlation via the international 10–20 system oriented for transcranial functional brain mapping , 2004, NeuroImage.

[33]  T. Terao,et al.  Polymorphisms of the σ1 receptor gene in schizophrenia: An association study , 2000 .

[34]  K. Hashimoto The NMDA Receptor Hypofunction Hypothesis for Schizophrenia and Glycine Modulatory Sites on the NMDA Receptors as Potential Therapeutic Drugs , 2006 .

[35]  Teruo Hayashi,et al.  Ca2+ Signaling via ς1-Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca2+Concentration , 2000 .

[36]  J. Henry,et al.  A meta-analytic review of verbal fluency performance following focal cortical lesions. , 2004, Neuropsychology.

[37]  H. Goldman,et al.  Treatment outcomes in schizophrenia: implications for practice, policy, and research. , 1995, Schizophrenia bulletin.

[38]  L. Werling,et al.  ς1 Receptor Agonist-Mediated Regulation ofN-Methyl-d-aspartate-Stimulated [3H]Dopamine Release Is Dependent upon Protein Kinase C , 2003, Journal of Pharmacology and Experimental Therapeutics.

[39]  Kiichi Ishiwata,et al.  Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. , 2006, Current pharmaceutical design.

[40]  A. Akaike,et al.  sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures. , 2000, European journal of pharmacology.

[41]  E. Portales-Casamar,et al.  The antidepressant-like effect induced by the sigma1 (σ1) receptor agonist igmesine involves modulation of intracellular calcium mobilization , 2002, Psychopharmacology.

[42]  David A. Boas,et al.  A Quantitative Comparison of Simultaneous BOLD fMRI and NIRS Recordings during Functional Brain Activation , 2002, NeuroImage.

[43]  M. Jackson,et al.  An N‐terminal double‐arginine motif maintains type II membrane proteins in the endoplasmic reticulum. , 1994, The EMBO journal.

[44]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[45]  T. Maurice,et al.  Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  H. Suwaki,et al.  Lack of association between sigma1 receptor gene variants and schizophrenia , 2004, Psychiatry and clinical neurosciences.

[47]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[48]  K. Hashimoto,et al.  High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [11C]SA4503 , 2007, Biological Psychiatry.

[49]  A. Villringer,et al.  Beyond the Visible—Imaging the Human Brain with Light , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  T. Goldberg,et al.  Letter and category fluency in schizophrenic patients: a meta-analysis , 2003, Schizophrenia Research.

[51]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors , 2007, Neuropsychopharmacology.

[52]  Daniel R Weinberger,et al.  Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. , 2006, Harvard review of psychiatry.

[53]  August B. Hollingshead,et al.  Two Factor Index of Social Position , 1957 .